This retrospective analysis compared two regimens of fludarabine combined with i.v. BU 6.4 mg/kg (FB2) or BU 12.8 mg/kg (FB4) for allografting of AML in first CR. A total of 437 patients (median age: 50 years) were administered FB2 (n = 225, 51%) or FB4 (n = 212, 49%). Median follow-up time was 28 months. Use of FB2 resulted in a longer time to neutrophil engraftment (17 vs 15 days, P o 0.0001) but no difference in incidence of grade II-IV acute (P = 0.54) or chronic GVHD (P = 0.51). In patients o 50 years of age, FB2 was associated with a higher 2-year cumulative incidence of relapse (33 ± 6% vs 20 ± 4%, P = 0.04), but there was no difference in 2-year leukemia-free survival (LFS) (P = 0.45), OS (P = 0.53) or non-relapse mortality (P = 0.17). In recipients ⩾ 50 years of age, FB2 resulted in better 2-year LFS (63 ± 4% vs 42 ± 7%, P = 0.02) and OS (68 ± 4% vs 45 ± 7%, P = 0.006); a lower 2-year non-relapse mortality, albeit not statistically significant (15 ± 3% vs 29 ± 6%, P = 0.06), was observed with FB2. FB2 is an effective and welltolerated regimen in patients ⩾ 50 years of age and does not compromise survival when used in patients o 50 years undergoing allogeneic transplantation for AML in first CR.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment modality for patients with AML and other hematologic malignancies. [1] [2] [3] [4] [5] [6] [7] Traditionally, allogeneic HCT was performed using myeloablative conditioning regimens that incorporated high doses of TBI plus chemotherapy or a combination of BU and CY, among other options. 1, 2, 8, 9 The resulting toxicity and consequent morbidity and mortality from the procedure, which exceeded 30% in most cases, limited the applicability of allo-HCT to patients of more advanced age or with a suboptimal performance status or a high HCT comorbidity index. [10] [11] [12] While the therapeutic benefits of allo-HCT are probably derived from both the myeloablative cytotoxicity of the regimen prior to transplantation as well as the immunological graft-versusleukemia effect of donor cells against host leukemic cells, a better understanding of the bona fide immunological benefits associated with the latter paved the way for the development of newer regimens, so called reduced-intensity (or reduced-toxicity) conditioning (RIC) regimens. [13] [14] [15] [16] RIC preparative regimens are associated with less treatment-associated toxicities and overall improvement in non-relapse mortality (NRM) in AML 3, 4, 17 and other malignancies. 18, 19 Availability of i.v. BU also translated into less regimen-associated toxicity when compared to oral BU, mostly due to predictable drug pharmacokinetics. [20] [21] [22] [23] Attempts to further reduce the resulting toxicity and consequent NRM from allo-HCT RIC conditioning regimens without compromising its efficacy remain an imperative goal to continue to broaden the applicability of allogeneic HCT, hence offering this potentially curative therapy to a higher number of patients. Such an endeavor might prove to be challenging, especially when considering that clinical, biological and genetic characteristics pertinent to the disease, as well as patient-related characteristics such as age, performance status and a high HCT comorbidity index, among others, are likely to influence the overall outcomes following allo-HCT in patients with AML. [24] [25] [26] [27] [28] A previous singleinstitution study comparing a myeloablative regimen of i.v. BU (Busulfex, Otsuka, Rockville, MD, USA; Busilvex, Pierre Fabre, Toulouse, France) plus CY (ivBUCY) with two RIC regimens of flurarabine plus i.v. BU 6.4 mg/kg (FB2) or i.v. BU 12.8 mg/kg (FB4) in patients with AML and myelodysplasia at various stages of the disease showed no difference in 2-year OS whether ivBUCY, FB2 or FB4 was used (50% vs 47% vs 49%, P = NS). 17 Unfortunately, only a small percentage of allografted recipients in that study were in first CR (CR1) (ivBUCY (n = 6,13%), FB2 (n = 15, 37%) and FB4 (n = 6, 24%)), not allowing a solid conclusion to be drawn about the impact of BU dose intensity among RIC regimens in this particular setting. 17 Accordingly, we performed a comparative analysis of two commonly used RIC regimens, namely FB2 (fludarabine plus i.v. BU 6.4 mg/kg ± 10%) and FB4 (fludarabine plus i.v. BU 12.8 mg/kg ± 10%), in 437 patients who underwent allogeneic HCT for AML in CR1 at EBMT participating transplant centers. Also, we evaluate the effect of BU dose intensity on the allograft recipient's age (o 50 vs ⩾ 50 years) and its impact on post-transplant outcomes.
Study design and eligibility criteria This is a retrospective non-randomized comparative registry study, representing the largest comparison of two aforementioned RIC regimens for allo-HCT in patients with AML in CR1 who underwent hematopoietic cell allografting at various participating centers of EBMT. The correlation between intensity of the conditioning regimen and recipient's age (o 50 vs ⩾ 50 years) and its effect on post-allograft outcomes at 2 years (NRM, cumulative incidence of relapse (CIR), leukemia-free survival (LFS) and OS) was also analyzed. Eligibility for inclusion in this analysis was as follows: patients had to be ⩾ Probabilities of LFS and OS were calculated using the KaplanMeier estimate. Cumulative incidence functions (CIFs) were used to estimate CIR and NRM in a competing-risks setting, since death and relapse are competing together. Cumulative incidences of grade II-IV acute GVHD, chronic GVHD and hepatic sinusoidal obstructive syndrome/veno-occlusive disease (SOS/VOD) were estimated taking into account death as a competing event.
Univariate analyses were done using log-rank test for OS and LFS, and Gray's test for CIF. Multivariate analyses were performed using Cox proportional-hazard model. Factors differing between two groups in terms of distribution were included in the model. The final model was stratified based on patient's age in order to take into account the interaction between regimen and age class (o 50 years and ⩾ 50 years). The hazard ratio between the two groups was estimated using the Mantel-Haenszel method. All tests were two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time-to-event Table 1 . Recipient, donor, disease and treatment-related characteristics
Recipient median age (range), years
Proportion of recipients o 50 vs ⩾ 50 years of age, n (%) 
RESULTS

Patient and treatment characteristics
A total of 437 patients (male = 232, 53%) with AML in CR1, of median age 50 (18-75) years, received a preparative regimen of FB2 (n = 225, 51%) or FB4 (n = 212, 49%) for allo-HCT between 2003 and 2010. The median follow-up (F/U) for all patients was 28 (2-89) months. The median F/U (range) of patients who received FB2 or FB4 as the allograft preparative regimen was 28 (2-85) and 27 (3-89) months, respectively (P = 0.48). Patients who received the FB2 regimen were older, had a lower incidence of cytomegalovirus (CMV) seropositivity and were less likely to receive an allograft from a CMV seropositive donor or to receive a graft from a MRD or BM cells (Table 1) . Patients conditioned with FB2 were more likely to receive ATG as part of the regimen (Table 1) . There was no difference in median time from diagnosis to achievement of CR1 or time from achievement of CR1 to allo-HCT or time from diagnosis to allo-HCT in patients receiving FB2 or FB4 (Table 2) .
Neutrophil engraftment Time-to-neutrophil engraftment was defined as the first of three consecutive days with an ANC ⩾ 500/μL. Allograft recipients conditioned with FB2 had a longer time to ANC engraftment (17 vs 15 days, P o0.0001) ( Table 2 ).
Acute and chronic GVHD, hepatic SOS/VOD There was no difference in the incidence of grade II-IV acute GVHD in patients conditioned with FB2 or FB4 (P = 0.54). Moreover, the 2-year cumulative incidence of chronic GVHD (any grade) was similar between patients conditioned with FB2 or FB4 (P = 0.51). Patients who received FB4 had a higher incidence of hepatic SOS/VOD (P = 0.03) ( Table 2) . NRM The 2-year cumulative incidence of NRM for all patients was 16 ± 2% (FB2 = 13 ± 2%, FB4 = 20 ± 3%, P = 0.17) ( Table 3) . We compared the 2-year NRM in patients conditioned with FB2 vs FB4 stratified by recipient's age (o50 vs ⩾ 50 years). There was no statistically significant difference in the 2-year NRM whether FB2 or FB4 was administered to allograft recipients o 50 (P = 0.17) or those ⩾ 50 years of age (P = 0.06) ( Table 3 ).
Relapse
The 2-year CIR for all was 23 ± 2% (FB2 = 25 ± 3%, FB4 = 23 ± 3%, P = 0.49). Patients o50 years of age who received FB2 had a significantly higher CIR compared to those receiving FB4 (33 ± 6% vs 20 ± 4%, P = 0.04). For patients ⩾ 50 years of age, there was no difference in the 2-year CIR whether FB2 (22 ± 3%) or FB4 (29 ± 6%) was administered (P = 0.42) ( Table 3) . Two-year LFS and OS Two-year OS for all patients was FB2 = 67 ± 3% and FB4 = 63 ± 3%, P = 0.57. OS did not differ when FB2 or FB4 was used in patients o50 years of age (P = 0.53) (Figure 1a and Table 3 ); however, FB2 resulted in superior 2-year OS in patients ⩾ 50 years of age (68 ± 4% vs 45 ± 7%, P = 0.006) (Figure 1b and Table 3) . Two-year LFS for all patients was 60 ± 2% (FB2 = 62 ± 3%, FB4 = 57 ± 3%, P = 0.58). LFS did not differ whether FB2 or FB4 was used in patients o 50 years of age (P = 0.45) (Figure 2a , Table 3 ); however, FB2 resulted in superior 2-year LFS in patients ⩾ 50 years of age (63 ± 4% vs 42 ± 7%, P = 0.02) (Figure 2b , Table 3 ). Abbreviations: CIR = cumulative incidence of relapse; LFS = leukemia-free survival; NRM = cumulative incidence of non-relapse mortality. Bold denotes statistically significant findings.
Multivariable analysis
2.78), P = 0.03) were found to adversely affect this outcome, whereas recipient CMV seropositivity (HR = 0.62 (0.39, 0.97), P = 0.04) appeared to confer a protective effect against relapse. Donor CMV seropositivity resulted in an adverse effect on LFS (HR = 1.73 (1.18, 2.55), P = 0.005) and OS (HR = 1.81 (1.2, 2.73), P = 0.005) ( Table 4) .
DISCUSSION
This analysis demonstrates that FB2 is a reasonable allo-HCT conditioning regimen to consider in patients ⩾ 50 years of age with AML in CR1 without an apparent increase in the 2-year CIR. In this particular patient population, the use of FB2 was associated with a twofold lower risk of NRM at 2 years from allografting, vis-à-vis FB4, albeit this difference was not statistically significant (P = 0.06). Moreover, FB2 resulted in superior 2-year LFS and OS, suggesting that higher BU doses, such as used in FB4, might not be necessary, and perhaps could be even detrimental in this older patient population. A higher dose of BU, as used in the FB4 regimen, resulted in a significantly lower CIR at 2 years in recipients o 50 years of age allografted for AML in CR1, suggesting a dose-effect benefit against disease relapse in this younger group. However, the benefit of using the FB4 regimen in these younger patients did not translate into an improvement in 2-year LFS or OS. As shown in Table 3 , administration of FB4 resulted in approximately twofold increase in NRM, albeit not statistically significant (P = 0.17); nevertheless, it is unclear whether the absence of an improved 2-year LFS and OS with FB4 was in part related to this effect.
Despite the fact that patients who received FB2 were significantly older (median age 57 vs 41 years, P o 0.0001) and more commonly allografted using PBSC from unrelated donors (Table 1) , which are known risks for GVHD, there was no observable difference in the incidence of grade II-IV acute GVHD or cumulative incidence of chronic GVHD (any grade) when Abbreviations: ATG = anti-thymocyte globulin; CIR = cumulative incidence of relapse; LFS = leukemia-free survival; MMUD = mismatched-unrelated donor; MRD = matched-related donor; MUD = matched unrelated donor; NRM = non-relapse mortality; +: seropositivity. Bold denotes statistically significant findings.
compared to recipients conditioned with FB4 (Table 2 ). This could be explained in part by a significantly higher use of ATG in the FB2 group (79% vs 33%, P o 0.0001). Use of ATG has been associated with reduced incidence and severity of acute and chronic GVHD. 29, 30 Patients who received FB4 achieved an earlier ANC engraftment (15 vs 17 days, P o0.0001) despite the fact that PBSC was more commonly used in allografted recipients conditioned with FB2 (Table 1) . Patients who received FB4 had a higher incidence of SOS/VOD (Table 2 ). This clearly demonstrates that higher doses of busulfan result in proportionally higher incidences of SOS/VOD 31 as previously described. However, it is important to emphasize that the observed incidence of SOS/VOD in this analysis remains lower than previously reported with use of more intense regimens. 11 Additionally, in the absence of specific details regarding AML induction and consolidation chemotherapy (ies) prior to allo-HCT or specific regimens used for acute GVHD prophylaxis, it is unclear whether administration of therapies such as gemtuzumab ozogamicin before allografting or use of the mTOR inhibitor sirolimus as prophylaxis for acute GVHD might have contributed to the higher incidence of SOS/VOD in subjects who received FB4. 32, 33 One inherent limitation of retrospective registry studies where two therapeutic interventions are compared, such as in our study, is the non-randomized nature of the analysis. In this case, participating EBMT centers reported the following reasons for selecting FB2: protocol driven 51%, subject's age 25%, presence of associated comorbidities 13% and a prior autologous HCT in 1%. No particular reason for choosing FB2 was reported in the remaining 10% of cases.
Previous 34 as well as recently published data show that CMV reactivation confers a protective effect against early (100-day) 35 or even later relapses 36 in patients who received an allo-HCT for AML. Even though we did not include incidence and time of CMV reactivation as a variable in our analysis, we observed a favorable effect of recipient CMV seropositivity at the time of transplantation, resulting in a lower CIR. One possible explanation for this finding is the fact that CMV seropositive recipients are obviously predisposed to develop CMV reactivation, hence possibly explaining the lower CIR observed. On the other hand, the adverse effect of donor CMV seropositivity on disease relapse and survival (LFS and OS) is noteworthy, but needs to be interpreted with caution because we did not perform an analysis comparing the effect of donor CMV seropositivity in relation to recipient CMV serologic status. A recent analysis of 16 628 patients who received an allo-HCT for de novo AML showed that donor CMV seropositivity (vs donor CMV-) was associated with a significantly decreased LFS and OS among CMV seronegative recipients in multivariable analysis. 37 Conversely, donor CMV serologic status did not appear to have a prognostic impact in CMV seropositive recipients. 37 In contrast to our study, previously published studies have reported a protective benefit against relapse of AML and ALL after allograting when CMV seropositive donors were selected. 38, 39 Future prospective multicenter studies aimed at evaluating the effect of donor CMV seropositivity on leukemia relapse and survival in relation to recipient CMV serologic status are certainly needed to better understand this relationship.
The presence of poor-risk cytogenetics did not impact adversely on LFS or OS. However, not surprisingly, it resulted in a higher 2-year CIR. Our analysis is, however, limited by the absence of data on expression of novel molecular prognostic markers of AML such as nucleophosmin-1 (NPM1) mutation, or allelic burden of FMS-related tyrosine kinase-3 (FLT-3) internal tandem duplication mutation and CCAAT/enhancer binding protein-α (CEBPA), among others. [40] [41] [42] [43] [44] [45] This limitation is inherent to retrospective registry studies. Our findings shall provide the basis for a prospective randomized trial to confirm the results of this study.
